Page last updated: 2024-12-09
beta-styrylacrylic acid
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
beta-styrylacrylic acid: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 1549512 |
| CHEMBL ID | 1095566 |
| CHEBI ID | 108600 |
| MeSH ID | M0053932 |
Synonyms (68)
| Synonym |
|---|
| BRD-K12345912-001-02-3 |
| (2e,4e)-5-phenyl-penta-2,4-dienoic acid |
| beta-styrylacrylic acid |
| nsc 63972 |
| 2,4-pentadienoic acid, 5-phenyl- |
| einecs 216-298-2 |
| 2,4-pentadienoic acid, 5-phenyl- (van) |
| nsc 109408 |
| nsc 1778 |
| nsc-1778 |
| nsc1778 |
| 2,4-pentadienoic acid, 5-phenyl-, |
| nsc-50789 |
| 28010-12-0 |
| nsc50789 |
| SDCCGMLS-0066886.P001 |
| BSPBIO_002523 |
| SPECTRUM5_000481 |
| (2e,4e)-5-phenylpenta-2,4-dienoic acid |
| 5-phenyl-2,4-pentadienoic acid |
| 1552-94-9 |
| NCGC00095798-01 |
| SPECTRUM203008 |
| NCGC00095798-02 |
| CHEBI:108600 |
| AKOS000304438 |
| 5-phenylpenta-2,4-dienoic acid |
| (e,e)-cinnamylideneacetic acid |
| CHEMBL1095566 |
| penta-2,4-dienoic acid, 5-phenyl-, (e,e)- |
| nsc 50789 |
| S3978 |
| CCG-40050 |
| 2,4-pentadienoicacid, 5-phenyl-, (2e,4e)- |
| cinnamylidene acetic acid |
| cinnamylideneacetic acid |
| 4-phenyl-1,3-butadiene-1-carboxylic acid |
| 5-phenylpenta-2,4-dienoicacid |
| juarezic acid |
| 5-phenylpenta-2,4-diecoic acid |
| (2e,4e)-5-phenyl-2,4-pentadienoic acid |
| 185152-35-6 |
| mfcd00014018 |
| J-515930 |
| J-507259 |
| sr-05000002408 |
| SR-05000002408-1 |
| 5-phenyl-penta-2,4-dienoic acid |
| J-009185 |
| CS-0030694 |
| HY-N7129 |
| 5-phenylpenta-(2e,4e)-dienoic acid |
| 5-phenyl-penta-2e,4e-dienoic acid |
| cinnamalacetic acid |
| AS-19080 |
| P2422 |
| BRD-K12345912-001-03-1 |
| AMY40722 |
| STL570453 |
| A883658 |
| 5-phenylpenta-2,4-dienoic acid; cinnamylideneacetic acid; cinnamalacetic acid;5-phenyl-2,4-pentadienoic acid |
| 1047682-56-3 |
| (4e)-5-phenylpenta-2,4-dienoic acid |
| (2e)-5-phenylpenta-2,4-dienoic acid |
| F10302 |
| EN300-1861098 |
| EN300-1709710 |
| 2,4-pentadienoicacid,5-phenyl-,(2e,4e)- |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (5)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID977599 | Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID477928 | Cytotoxicity against human PANC1 cells in nutrient-deprived condition assessed as preferential cell death after 24 hrs by trypan blue dye exclusion method | 2010 | Journal of natural products, Apr-23, Volume: 73, Issue:4 | Study on the constituents of Mexican propolis and their cytotoxic activity against PANC-1 human pancreatic cancer cells. |
| AID592088 | Antihemorrhagic activity in ddY mouse assessed as inhibition of Protobothrops flavoviridis venom-induced hemorrhage incubated with compound for 10 mins measured after 24 hrs | 2011 | Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7 | Contribution of cinnamic acid analogues in rosmarinic acid to inhibition of snake venom induced hemorrhage. |
| AID977602 | Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (4)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 13.13
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.13) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||